Notes
epidermal growth factor receptor
EURopean TArceva vs Chemotherapy
Reference
Vergnenegre A, et al. Economical analysis of first line treatment by erlotinib in an EGFR mutated population with advanced non-small cell lung cancers NSCLC. Journal of Thoracic Oncology : 18 Feb 2016. Available from: URL: http://doi.org/10.1016/j.jtho.2016.02.004
Rights and permissions
About this article
Cite this article
Erlotinib cost-effective option in EGFR-mutated NSCLC. PharmacoEcon Outcomes News 748, 15 (2016). https://doi.org/10.1007/s40274-016-2866-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2866-y